Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with mBC on or after 1 January 2015.
Had HR+/HER2- test results.
Received ribociclib and endocrine therapy in 1L treatment.
Patients had a gap of 90 days or less between mBC diagnosis date and the first structured EHR activity (e.g., lab tests and prescriptions) after metastatic diagnosis date.
You may not be if
None identified.
Clareo Health | A Study of Real-world Outcomes Among Patients Treated With Ribociclib
